Jesse M. Cedarbaum

17.3k total citations · 3 hit papers
139 papers, 10.6k citations indexed

About

Jesse M. Cedarbaum is a scholar working on Neurology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Jesse M. Cedarbaum has authored 139 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Neurology, 34 papers in Cellular and Molecular Neuroscience and 28 papers in Physiology. Recurrent topics in Jesse M. Cedarbaum's work include Parkinson's Disease Mechanisms and Treatments (53 papers), Neurological disorders and treatments (24 papers) and Amyotrophic Lateral Sclerosis Research (15 papers). Jesse M. Cedarbaum is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (53 papers), Neurological disorders and treatments (24 papers) and Amyotrophic Lateral Sclerosis Research (15 papers). Jesse M. Cedarbaum collaborates with scholars based in United States, Israel and France. Jesse M. Cedarbaum's co-authors include George K. Aghajanian, Nancy Stambler, Errol Malta, Dana Hilt, Arline Nakanishi, H. Michael Arrighi, Alex Ward, Hiroshi Mitsumoto, Vivien Wong and Fletcher McDowell and has published in prestigious journals such as Science, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Jesse M. Cedarbaum

139 papers receiving 10.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function

1999 2.5k citations Jesse M. Cedarbaum, Nancy Stambler et al. Journal of the Neurological Sciences profile →
Catecholamine receptors on locus coeruleus neurons: Pharmacological characterization

1977 489 citations Jesse M. Cedarbaum et al. profile →
Mild cognitive impairment: Disparity of incidence and prevalence estimates

2012 414 citations Jesse M. Cedarbaum et al. Alzheimer s & Dementia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jesse M. Cedarbaum United States	44	4.8k	3.3k	2.0k	1.8k	1.8k	139	10.6k
Reinhard Dengler Germany	59	6.8k 1.4×	2.8k 0.8×	2.0k 1.0×	1.5k 0.8×	2.1k 1.2×	378	12.4k
Eldad Melamed Israel	65	6.0k 1.3×	4.5k 1.4×	3.7k 1.9×	1.5k 0.9×	1.3k 0.7×	228	13.6k
Lucette Lacomblez France	47	7.0k 1.5×	1.6k 0.5×	2.4k 1.2×	1.6k 0.9×	3.6k 2.0×	154	10.3k
Jan Kassubek Germany	60	7.6k 1.6×	3.0k 0.9×	1.7k 0.9×	1.4k 0.8×	1.7k 1.0×	437	13.6k
Tibor Hortobágyi Hungary	43	3.2k 0.7×	1.2k 0.4×	2.7k 1.3×	2.2k 1.2×	1.5k 0.9×	227	8.3k
Gabriele Siciliano Italy	52	2.6k 0.5×	2.3k 0.7×	4.6k 2.3×	2.2k 1.3×	872 0.5×	429	10.1k
Jillian J. Kril Australia	59	4.7k 1.0×	2.0k 0.6×	2.2k 1.1×	3.6k 2.1×	478 0.3×	195	11.9k
Vladimir Kostić Serbia	53	6.4k 1.3×	3.4k 1.0×	1.8k 0.9×	1.1k 0.6×	297 0.2×	369	10.4k
David Devos France	54	4.5k 0.9×	1.8k 0.5×	2.6k 1.3×	926 0.5×	483 0.3×	234	9.4k
Ole‐Bjørn Tysnes Norway	44	5.6k 1.2×	1.3k 0.4×	1.5k 0.7×	1.4k 0.8×	375 0.2×	192	8.3k

Countries citing papers authored by Jesse M. Cedarbaum

Since Specialization

Citations

This map shows the geographic impact of Jesse M. Cedarbaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse M. Cedarbaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse M. Cedarbaum more than expected).

Fields of papers citing papers by Jesse M. Cedarbaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesse M. Cedarbaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse M. Cedarbaum. The network helps show where Jesse M. Cedarbaum may publish in the future.

Co-authorship network of co-authors of Jesse M. Cedarbaum

This figure shows the co-authorship network connecting the top 25 collaborators of Jesse M. Cedarbaum. A scholar is included among the top collaborators of Jesse M. Cedarbaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse M. Cedarbaum. Jesse M. Cedarbaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Yuting, Minhua Yang, Kyle Fraser, et al.. (2024). Quantification of cinpanemab (BIIB054) binding to α-synuclein in cerebrospinal fluid of phase 1 single ascending dose samples. Journal of Pharmacology and Experimental Therapeutics. 392(1). 100003–100003. 3 indexed citations

Mirelman, Anat, Eran Gazit, Alice Nieuwboer, et al.. (2023). Digital Mobility Measures: A Window into Real‐World Severity and Progression of Parkinson's Disease. Movement Disorders. 39(2). 328–338. 14 indexed citations

Bashat, Dafna Ben, Avner Thaler, Einat Even‐Sapir, et al.. (2022). Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s disease. npj Parkinson s Disease. 8(1). 139–139. 16 indexed citations

Kizony, Rachel, Jesse M. Cedarbaum, Noa Bregman, et al.. (2021). Quantitative digital clock drawing test as a sensitive tool to detect subtle cognitive impairments in early stage Parkinson's disease. Parkinsonism & Related Disorders. 90. 84–89. 8 indexed citations

Thaler, Avner, Nir Giladi, Tanya Gurevich, et al.. (2021). Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. Journal of Parkinson s Disease. 11(3). 1285–1296. 20 indexed citations

Hutchison, R. Matthew, Karleyton C. Evans, Tara Fox, et al.. (2021). Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson’s disease trial. BMC Neurology. 21(1). 459–459. 13 indexed citations

Mirelman, Anat, Inbar Hillel, Lynn Rochester, et al.. (2020). Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. Movement Disorders. 35(6). 959–968. 40 indexed citations

Droby, Amgad, Tanya Gurevich, Meir Kestenbaum, et al.. (2020). Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches. Journal of the Neurological Sciences. 417. 117059–117059. 4 indexed citations

Bryś, Mirosław, Laura Fanning, Serena Hung, et al.. (2019). Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054. Movement Disorders. 34(8). 1154–1163. 139 indexed citations

10.

Bryś, Mirosław, Aaron Ellenbogen, Laura Fanning, et al.. (2018). Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Anti-Alpha-Synuclein Antibody BIIB054 in Patients with Parkinson’s Disease (S26.001). Neurology. 90(15_supplement). 17 indexed citations

11.

Merchant, Kalpana, Jesse M. Cedarbaum, Patrik Brundin, et al.. (2018). A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson s Disease. 9(1). 31–61. 38 indexed citations

12.

Cedarbaum, Jesse M., Mark Jaros, C. Hernandez, et al.. (2012). Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials. Alzheimer s & Dementia. 9(1S). S45–55. 95 indexed citations

13.

Browning, David J., Peter Sonkin, Henry L. Hudson, et al.. (2006). Results of a Phase I, Dose–Escalation, Safety, Tolerability, and Bioactivity Study of Intravitreous VEGF Trap in Patients With Neovascular Age–Related Macular Degeneration. Investigative Ophthalmology & Visual Science. 47(13). 2144–2144. 1 indexed citations

14.

Wiegand, Stanley J., T. Michael Nork, Paul E. Miller, et al.. (2005). VEGF Trap Both Prevents Experimental Choroidal Neovascularization and Causes Regression of Established Lesions in Non–Human Primates. Investigative Ophthalmology & Visual Science. 46(13). 1411–1411. 4 indexed citations

15.

Parkman, Henry P., Satish S.C. Rao, James C. Reynolds, et al.. (2003). Neurotrophin-3 Improves Functional Constipation. The American Journal of Gastroenterology. 98(6). 1338–1347. 59 indexed citations

16.

Aisen, Mindy, et al.. (1992). Clinical and Pharmacokinetic Aspects of High Dose Oral Baclofen Therapy. PubMed. 15(4). 211–216. 28 indexed citations

17.

Guttman, Mark, Gabriel C. Léger, Jesse M. Cedarbaum, et al.. (1992). 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals of Neurology. 31(6). 638–643. 34 indexed citations

18.

Eidelberg, David, James R. Moeller, Vijay Dhawan, et al.. (1990). The metabolic anatomy of Parkinson's disease: Complementary [¹⁸F]fluorodeoxyglucose and [¹⁸F]fluorodopa positron emission tomographic studies. Movement Disorders. 5(3). 203–213. 165 indexed citations

19.

Cedarbaum, Jesse M., Henn Kutt, & Fletcher McDowell. (1989). A pharmacokinetic and pharmacodynamic comparison of Sinemet CR (50/200) and standard Sinemet (25/100).. PubMed. 39(11 Suppl 2). 38–44; discussion 59. 33 indexed citations

20.

Porter, Linda, Jesse M. Cedarbaum, Dennis D.M. O'Leary, B.B. Stanfield, & Hiroshi Asanuma. (1987). The physiological identification of pyramidal tract neurons within transplants in the rostral cortex taken from the occipital cortex during development. Brain Research. 436(1). 136–142. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact